Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAmgen is a diversified pharmaceutical giant with high net margins. It reported nearly $8.1 billion in free cash flow for fiscal 2025.
Amgen is a diversified pharmaceutical company with a global presence, operating in approximately 100 countries. The company reported nearly $8.1 billion in free cash flow for fiscal 2025, according to Nasdaq Markets.
Amgen's business spans several core areas, including inflammation, rare disease, and oncology. Its revenue for fiscal 2025 was largely accounted for by McKesson, Cencora, and Cardinal Health, which together made up 77% of its revenue, as per Motley Fool.
Axsome Therapeutics, on the other hand, focuses on central nervous system disorders such as depression and narcolepsy. The company is prioritizing the commercialization of its newer therapies to reach long-term profitability, as reported by Motley Fool.
Brief written by urgent.news from Nasdaq Markets, Motley Fool — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
